Brookline, Massachusetts Clinical Trials

A listing of Brookline, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

measurable disease
carcinoma
radical vulvectomy
cancer
primary tumor
Massachusetts General Hospital Cancer Center
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Preoperative Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation is known to increase morbidity and mortality and contribute to longer post-implant hospital length of stay. Since RVF is difficult to predict and can …

right ventricular failure
ventricular dysfunction
Massachusetts General Hospital
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

measurable disease
biologics
karnofsky performance status
cancer
neutrophil count
Dana-Farber Cancer Institute
 (2.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow …

acoustic neuroma
measurable disease
brigatinib
karnofsky performance status
nf2 gene
Dana Farber Cancer Institute
 (2.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women

The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth. This poor outcome is linked to the racial and ethnic disparities that disproportionately effects low income and black women. …

HealthCore
 (3.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: Implantation …

carcinoma
neutrophil count
prostatectomy
Brigham and Women's Hospital
 (2.5 away) Contact site
  • 2 views
  • 19 Feb, 2024
  • 1 location
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

adjuvant
measurable disease
estrogen
cancer
keytruda
Dana Farber Cancer Institute
 (2.3 away) Contact site
  • 8 views
  • 19 Feb, 2024
  • 1 location
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

castration-resistant prostate cancer
cancer
adenocarcinoma of prostate
androgen suppression
testosterone
Dana Farber Cancer Institute
 (2.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

measurable disease
pomalidomide
immunotherapeutic agent
daratumumab
thalidomide
Investigational Site Number 8400003
 (2.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
Test trial v7.2 (May 13) - Test 1 (Acro - Test 1)

Test trial v7.2 (May 13) - Test 1

US-Site 1
 (3.3 away) Contact site
  • 0 views
  • 09 Jul, 2026
  • +2 other locations